MARIMED INC.
Close on Oct 19, 2026
- Market cap
- $22.78M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $39.50M | $-0.01 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 11, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | After market close | $40.80M | $-0.01 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | After market close | $37.96M | $-0.01 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 5, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $40.60M | $0.00 | $0.50 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Nov 6, 2024, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Capital Expenditures | full-year 2024 | $11.00M | New |
| Non-GAAP Adjusted EBITDAnon-GAAP | full-year 2024 | -20% to -18% growth | New |
| Revenue Growth | full-year 2024 | 6% to 8% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Marimed filed with the SEC
MariMed Files Definitive Proxy Statement for Special Meeting of Stockholders to Approve Proposed Reverse Stock Split
Other events · EX-99.1 to Form 8-K
MariMed Reports Second Quarter 2026 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports First Quarter 2026 Earnings
Results of operations · EX-99.1 to Form 8-K
and Full Year 2025 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Third Quarter 2025 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Second Quarter 2025 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports First Quarter 2025 Earnings
Results of operations · EX-99.1 to Form 8-K
and Full Year 2024 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Third Quarter 2024 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Second Quarter 2024 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports First Quarter 2024 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Fourth Quarter and Full Year 2023 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Closes $58.7 Million Debt Refinancing
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
MariMed Reports Third Quarter 2023 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports Second Quarter 2023 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Reports First Quarter 2023 Earnings
Results of operations · EX-99.1 to Form 8-K
MariMed Expands Board With the Addition of Kathleen Tucker
Executive or director change · Other events · EX-99.1 to Form 8-K
and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
MariMed Closes $35 Million Credit Facility
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
MariMed Appoints Jon Levine as Interim Chief Executive Officer
Other events · EX-99.1 to Form 8-K
MariMed Mourns the Passing of Robert Fireman, Chairman, CEO
Other events · EX-99.1 to Form 8-K
MariMed Reports Third Quarter 2022 Earnings
Results of operations · EX-99.1 to Form 8-K
Appoints Jon Levine as President
Executive or director change · Other events · EX-99.1 to Form 8-K
Reports Second Quarter 2022 Earnings
Results of operations · EX-99.1 to Form 8-K
Reports First Quarter 2022 Earnings
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Receives Maryland State Approval for
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Quarter 2021 Financial Results Conference Call
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K